超速效胰岛素

超速效胰岛素是一种新型胰岛素制剂，旨在模拟人体对膳食的生理性胰岛素反应，以改善餐后血糖控制。该胰岛素种类主要包括超速效门冬胰岛素和超速效赖脯胰岛素两类。^[1]

超速效门冬胰岛素

超速效门冬胰岛素是诺和诺德公司(Novo Nordisk)于2017年推出的一种胰岛素制剂，获得了美国食品药品监督局(FDA)的批准^[1]。

超速效赖脯胰岛素

超速效赖脯胰岛素是礼来公司(Eli Lilly and Company)在2020年获得美国FDA批准的胰岛素制剂。与传统赖脯胰岛素相比，超速效赖脯胰岛素更接近人体对膳食的生理性胰岛素反应，可以改善对餐后血糖的控制。其特殊配方包括曲前列素和柠檬酸酸盐，可以促进胰岛素快速吸收，从而在血清中的出现时间提早、暴露量减少，降低了餐后延迟低血糖的几率^[2]。^[1]

多项随机对照临床研究表明，超速效赖脯胰岛素在1型和2型糖尿病患者中的使用效果良好^[3]^[4]。与传统赖脯胰岛素相比，超速效赖脯胰岛素在餐后血糖控制方面具有显著优势，且安全性相当^[1]。不良反应方面，超速效赖脯胰岛素并未增加与传统赖脯胰岛素相比的显著差异^[1]。

参考文献

^ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 Zhou, Lihua; Qu, Duoduo; Zhao, Xiaolong. Focus on a special tool for postprandial glucose control: Ultra rapid lispro. Chinese Science Bulletin. 2023-06-01. doi:10.1360/TB-2023-0508.
^ Leohr, J; Dellva, MA; Carter, K; LaBell, E; Linnebjerg, H. Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.. Clinical pharmacokinetics. 2021-11, 60 (11): 1423–1434. PMID 34041713. doi:10.1007/s40262-021-01030-0.
^ Kazda, C; Leohr, J; Liu, R; Reddy, S; Dellva, MA; Loh, MT; Hardy, T; Plum-Mörschel, L. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.. Diabetes, obesity & metabolism. 2022-02, 24 (2): 196–203. PMID 34595812. doi:10.1111/dom.14563.
^ Leohr, J; Kazda, C; Liu, R; Reddy, S; Dellva, MA; Matzopoulos, M; Loh, MT; Hardy, T; Klein, O; Kapitza, C. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.. Diabetes, obesity & metabolism. 2022-02, 24 (2): 187–195. PMID 34605142. doi:10.1111/dom.14561.

[TB-2023-0508-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 Zhou, Lihua; Qu, Duoduo; Zhao, Xiaolong. Focus on a special tool for postprandial glucose control: Ultra rapid lispro. Chinese Science Bulletin. 2023-06-01. doi:10.1360/TB-2023-0508.

[2] Leohr, J; Dellva, MA; Carter, K; LaBell, E; Linnebjerg, H. Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.. Clinical pharmacokinetics. 2021-11, 60 (11): 1423–1434. PMID 34041713. doi:10.1007/s40262-021-01030-0.

[3] Kazda, C; Leohr, J; Liu, R; Reddy, S; Dellva, MA; Loh, MT; Hardy, T; Plum-Mörschel, L. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.. Diabetes, obesity & metabolism. 2022-02, 24 (2): 196–203. PMID 34595812. doi:10.1111/dom.14563.

[4] Leohr, J; Kazda, C; Liu, R; Reddy, S; Dellva, MA; Matzopoulos, M; Loh, MT; Hardy, T; Klein, O; Kapitza, C. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.. Diabetes, obesity & metabolism. 2022-02, 24 (2): 187–195. PMID 34605142. doi:10.1111/dom.14561.

[1]

[2]

[3]

[4]